MSH6 gene
mutS homolog 6

Normal Function

The *MSH6* gene provides instructions for making a protein that plays an essential role in repairing DNA. This protein helps fix errors that are made when DNA is copied (DNA replication) in preparation for cell division. The MSH6 protein joins with another protein called MSH2 (produced from the *MSH2* gene) to form a two-protein complex called a dimer. This complex identifies locations on the DNA where errors have been made during DNA replication. Additional proteins, including another dimer called the MLH1-PMS2 dimer, then repair the errors by removing the mismatched DNA and replicating a new segment. The *MSH6* gene is a member of a set of genes known as the mismatch repair (MMR) genes.

Health Conditions Related to Genetic Changes

**Constitutional mismatch repair deficiency syndrome**

More than 15 mutations in the *MSH6* gene have been associated with a condition called constitutional mismatch repair deficiency (CMMRD) syndrome. Individuals with this condition are at increased risk of developing cancers of the colon (large intestine) and rectum (collectively referred to as colorectal cancer), brain, and blood (leukemia or lymphoma). These cancers usually first occur in childhood, with the vast majority of cancers in CMMRD syndrome diagnosed in people under the age of 18. Many people with CMMRD syndrome also develop changes in skin coloring (pigmentation), similar to those that occur in a condition called neurofibromatosis type 1.

Individuals with CMMRD syndrome inherit two *MSH6* gene mutations, one from each parent, while people with Lynch syndrome (described below) have a mutation in one copy of the *MSH6* gene.

*MSH6* gene mutations result in near or complete loss of MSH6 protein production. A shortage of this protein eliminates mismatch repair activity and prevents the proper repair of DNA replication errors. These errors accumulate as the abnormal cells continue to divide. The errors disrupt other genes involved in important cellular processes, such as controlling cell growth and division (proliferation). If cell growth is uncontrolled, it can lead to childhood cancer in people with CMMRD syndrome.

It is thought that the features of neurofibromatosis type 1 in people with CMMRD syndrome are due to genetic changes in the *NF1* gene that result from loss of mismatch repair. These changes are present only in certain cells (somatic mutations), whereas *NF1* gene mutations that are present in all cells of the body cause neurofibromatosis type 1.
Lynch syndrome

Mutations in the *MSH6* gene have been reported in about 13 percent of families with Lynch syndrome that have an identified gene mutation. Lynch syndrome increases the risk of many types of cancer, particularly colorectal cancer. People with Lynch syndrome also have an increased risk of cancers of the endometrium (lining of the uterus), ovaries, stomach, small intestine, gallbladder ducts, upper urinary tract, and brain. By age 75, the risk of developing one of these cancers is 60 percent for women and 40 percent for men with an *MSH6* gene mutation. Endometrial cancer is especially common in women with Lynch syndrome caused by *MSH6* gene mutations.

*MSH6* gene mutations involved in this condition lead to the production of an abnormally short, nonfunctional MSH6 protein; a partially active version of the protein; or no protein product from one copy of the gene. A decrease in functional MSH6 protein leads to an increase in unrepaired DNA errors during cell division. The errors accumulate as the cells continue to divide, which may cause the cells to function abnormally, increasing the risk of tumor formation in the colon or another part of the body.

Because there is some functional MSH6 protein produced from the normal copy of the gene, mismatch repair activity in Lynch syndrome is reduced but not absent, as it is in CMMRD syndrome (described above). This difference in DNA repair activity levels likely explains why cancers in Lynch syndrome generally develop in adulthood while those in CMMRD syndrome often affect children.

In a small number of people, mutations in the *MSH6* gene cause a variant of Lynch syndrome called Muir-Torre syndrome. In addition to colorectal cancer, people with this condition have an increased risk of developing several uncommon skin tumors. These rare skin tumors include sebaceous adenomas and carcinomas, which occur in glands that produce an oily substance called sebum (sebaceous glands). Multiple rapidly growing tumors called keratoacanthomas may also occur, usually on sun-exposed areas of skin.

Ovarian cancer
Chromosomal Location

Cytogenetic Location: 2p16.3, which is the short (p) arm of chromosome 2 at position 16.3

Molecular Location: base pairs 47,783,082 to 47,806,954 on chromosome 2 (Homo sapiens Updated Annotation Release 109.20200522, GRCh38.p13) (NCBI)

Credit: Genome Decoration Page/NCBI

Other Names for This Gene

- G-T binding protein
- G/T mismatch-binding protein
- GTBP
- mutS (E. coli) homolog 6
- MutS-alpha 160 kDa subunit
- mutS homolog 6 (E. coli)

Additional Information & Resources

Educational Resources

- Cancer Medicine (sixth edition, 2003): DNA Mismatch Repair Gene Defects and HNPCC
  https://www.ncbi.nlm.nih.gov/books/NBK12469/#A1595

- Molecular Biology of the Cell (fourth edition, 2002): Defects in DNA Mismatch Repair Provide an Alternative Route to Colorectal Cancer
  https://www.ncbi.nlm.nih.gov/books/NBK26902/#A4345

- National Human Genome Research Institute: The Genomic Services Research Program (GSRP): Study of People with Unexpected Genetic Results
  https://www.genome.gov/Current-NHGRI-Clinical-Studies/Genomic-Services-Research-Program

Clinical Information from GeneReviews

- Lynch Syndrome
  https://www.ncbi.nlm.nih.gov/books/NBK1211
Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28MSH6%5BTIAB%5D%29+OR+%28mutS+homolog+6%5BTIAB%5D%29%29+AND+%28g-t+mismatch-binding+protein%5BNM%5D%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- MUIR-TORRE SYNDROME
  http://omim.org/entry/158320
- MutS HOMOLOG 6
  http://omim.org/entry/600678
- NEUROFIBROMATOSIS, TYPE I
  http://omim.org/entry/162200

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
  http://atlasgeneticsoncology.org/Genes/MSH6ID344ch2p16.html
- ClinVar
  https://www.ncbi.nlm.nih.gov/clinvar?term=MSH6%5Bgene%5D
- HGNC Gene Symbol Report
  https://www.genenames.org/data/gene-symbol-report/%21/hgnc_id/HGNC:7329
- Monarch Initiative
  https://monarchinitiative.org/gene/NCBIGene:2956
- NCBI Gene
  https://www.ncbi.nlm.nih.gov/gene/2956
- UniProt
  https://www.uniprot.org/uniprot/P52701

Sources for This Summary

- Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer. 2005;4(4):323-33. Review.
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16341812
- Cederquist K, Emanuelsson M, Góransson I, Holinski-Feder E, Müller-Koch Y, Golovleva I, Grönberg H. Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double primary cancers of the colorectum and the endometrium: a population-based study in northern Sweden. Int J Cancer. 2004 Apr 10;109(3):370-6. Erratum in: Int J Cancer. 2005 Jul 20;115(6):1011.
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14961575
• Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol. 2008 Feb;21(2):159-64. Epub 2007 Dec 7. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18065960

• Dominguez-Valentín M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Köstner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Büttner R, Görgens H, Holinski-Feder E, Morak M, Holzapfel S, Hübner R, Knebel Doeberitz MV, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, Schmieg W, Vangala D, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkielsen C, Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Laloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin JP, Nielsen M, Møller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020 Jan;22(1):15-25. doi: 10.1038/s41436-019-0596-9. Epub 2019 Jul 24. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31337882

• Edelbrock MA, Kaliyaperumal S, Williams KJ. Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. Mutat Res. 2013 Mar-Apr;743-744:53-66. doi: 10.1016/j.mrfmmm.2012.12.008. Epub 2013 Feb 4. Review. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23391514 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659183/

• Kohlmann W, Gruber SB. Lynch Syndrome. 2004 Feb 5 [updated 2014 May 22]. In: Pagon RA, Adam MP, Ardinger HH, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301390

• Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003 Mar 6;348(10):919-32. Review. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12621137

• OMIM: MutS HOMOLOG 6 http://omim.org/entry/600678

• Pande M, Wei C, Chen J, Amos CI, Lynch PM, Lu KH, Lucio LA, Boyd-Rogers SG, Bannon SA, Mork ME, Frazier ML. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry. Fam Cancer. 2012 Sep;11(3):441-7. doi: 10.1007/s10689-012-9534-6. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22714864 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475767/

• Peltonäkki P. Lynch syndrome genes. Fam Cancer. 2005;4(3):227-32. Review. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16136382
• Schneider NB, Pastor T, Paula AE, Achatz MI, Santos ÂRD, Vianna FSL, Rosset C, Pinheiro M, Ashton-Prolla P, Moreira MÂM, Palmero El; Brazilian Lynch Syndrome Study Group. Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome. Cancer Med. 2018 May;7(5):2078-2088. doi: 10.1002/cam4.1316. Epub 2018 Mar 25.
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29575718
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943474/

• Tamura K, Kaneda M, Futagawa M, Takeshita M, Kim S, Nakama M, Kawashita N, Tatsumi-Miyajima J. Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome. Int J Clin Oncol. 2019 Sep;24(9):999-1011. doi: 10.1007/s10147-019-01494-y. Epub 2019 Jul 4. Review. Erratum in: Int J Clin Oncol. 2019 Jul 31;:
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31273487

Reprinted from Genetics Home Reference:
https://ghr.nlm.nih.gov/gene/MSH6

Reviewed: April 2020
Published: June 23, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services